Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y12 antagonists in an ex-vivo canine model

Thrombosis Research

Volumn 130, Issue 4, 2012, Pages 622-628

  Ravnefjord, Anna ^a   Weilitz, Jessika ^a   Emanuelsson, Britt Marie ^a   Van Giezen, J J J ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiplatelet therapy; Cangrelor; Clopidogrel; Preclinical; Ticagrelor

Indexed keywords

CANGRELOR; CLOPIDOGREL; TICAGRELOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BINDING; EXPERIMENTAL DOG; IMPEDANCE AGGREGOMETRY; MALE; MEASUREMENT; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ANIMALS; BLOOD PLATELETS; DOGS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84866259452     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.07.021     Document Type: Article

References (34)

1. J.P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, and F. Fernandez-Aviles Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
3. J.-M. Pereillo, M. Maftouh, A. Andrieu, M.F. Uzabiaga, O. Fedeli, and P. Savi Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
4. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, and C. Wei Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease, the ONSET-OFFSET study Circulation 120 2009 2577 2585
5. X. Boulenc, N. Djevli, J. Shi, L. Perrin, W. Brian, and R. Van Horn Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite Drug Metab Dispos 40 2012 187 197
6. B. Springthorpe, A. Bailey, P. Barton, T.N. Birkinshaw, R.V. Bonnert, and R.C. Brown From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis Bioorg Med Chem Lett 17 2007 6013 6018
7. 12 receptor antagonist Cardiovasc Ther 27 2009 259 274
8. Brilique, summary of product characteristics, 2010 Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001241/WC500100494.pdf 2010 Last accessed 7 December 2011
9. T.M. Brilinta US full prescribing information, July 2011 Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022433s000lbl.pdf Last accessed 7 December 2011
10. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
11. R. Teng, and K. Butler Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects Eur J Clin Pharmacol 66 2010 487 496
12. K. Butler, and R. Teng Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers Br J Clin Pharmacol 70 2010 65 77
13. 12 antagonists Semin Thromb Hemost 31 2005 195 204
14. 12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model Arterioscler Thromb Vasc Biol 23 2003 357 362
15. R.F. Storey, K.G. Oldroyd, and R.G. Wilcox Open multicenter study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes Thromb Haemost 85 2001 401 407
16. 12 receptor antagonist J Clin Pharmacol 50 2010 27 35
17. R.F. Storey, R.G. Wilcox, and S. Heptinstall Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease Platelets 13 2002 407 413
18. H.J. Bouman, J.W. van Werkum, C.M. Hackeng, N. Clappers, and J.M. ten Berg Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects Neth Heart J 17 2009 195 198
19. S.R. Steinhubl, J.J. Oh, J.H. Oestreich, S. Ferraris, R. Charnigo, and W.S. Akers Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect Thromb Res 121 2008 527 534
20. O. Tóth, A. Calatzis, S. Penz, H. Losonczy, and W. Siess Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood Thromb Haemost 96 2006 781 788
21. D. Sibbing, S. Braun, S. Jawansky, W. Vogt, J. Mehilli, and A. Schömig Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 2008 121 126
22. H. Sillén, M. Cook, and P. Davis Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 2299 2306
23. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
24. P. Savi, J.M. Pereillo, M.F. Uzabiaga, J. Combalbert, C. Picard, and J.P. Maffrand Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
25. P. Savi, C. Labouret, N. Delesque, F. Guette, J. Lupker, and J.M. Herbert P2Y(12), a new platelet ADP receptor, target of clopidogrel Biochem Biophys Res Commun 283 2001 379 383
26. D. Taubert, A. Kastrati, S. Harlfinger, O. Gorchakova, A. Lazar, and N. von Beckerath Pharmacokinetics of clopidogrel after administration of a high loading dose Thromb Haemost 92 2004 311 316
27. J.-S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
28. 12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis Thromb Res 124 2009 565 571
29. G.L. Dale, R.F. Wolf, L.A. Hynes, P. Friese, and S.A. Burstein Quantitation of platelet life span in splenectomized dogs Exp Hematol 24 1996 518 523
30. D.C. Giuliani, E.H. Ford, and B.S. Morse A rapid method for estimating mean platelet survival time J Nucl Med 30 1989 1550 1553
31. K. Hagihara, M. Kazui, H. Ikenaga, T. Nanba, K. Fusegawa, and M. Takahashi Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs Xenobiotica 39 2009 218 226
32. J.J.J. van Giezen Optimizing platelet inhibition Eur Heart J 10 Suppl. D 2008 D23 D29
33. 12 receptor oligomers and partitions them out of lipid rafts Proc Natl Acad Sci U S A 103 2006 11069 11074
34. 12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function J Thromb Haemost 6 2008 1153 1159